Kellie Sprague

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3

Mark J. Levis, Mehdi Hamadani, Brent R. Logan, Richard John Jones et autres

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. …

us, kr, de, jp, gb, il, au (code pays fourni par la source)

Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results–Medicare Database

Andreas Klein, Kellie Sprague, Gunjan L. Shah, Susan Kenyon Parsons et autres

In the past decade, the number of autologous hematopoietic stem cell transplants (Auto HSCT) for older patients with multiple myeloma (MM) has increased dramatically, as has the cost of transplantation. The cost-effectiveness of this modality in patients over age 65 is unclear. …

us (code pays fourni par la source)

Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902

Francine M. Foss, Victoria Wang, Selina M. Luger, Opeyemi A. Jegede et autres

BACKGROUND: Extracorporeal photopheresis (ECP) is an immunomodulatory cellular therapy which has been shown to induce a tolerogenic state in patients with acute and chronic graft-vs-host disease. ECOG-ACRIN explored the activity of ECP as a part of a reduced intensity conditioning regimen in …

us, ca (code pays fourni par la source)

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Xun Ma, Sandy Wai Kuan Wong, Ping Zhou, Chakra P. Chaulagain et autres

BACKGROUND: The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells. Because mobilized CD34+ cells are critical for stem cell transplant, we investigated the in vitro activity of daratumumab on mobilized …

us (code pays fourni par la source)

Clustered incidence of adult acute promyelocytic leukemia

Andrew Mark Brunner, Peter Geon Kim, Hossein S.M. Sadrzadeh, Benjamin Jacob Drapkin et autres

us (code pays fourni par la source)

Clinicopathologic characteristics of secondary squamous cell carcinoma of head and neck in survivors of allogeneic hematopoietic stem cell transplantation for hematologic malignancies

Chakra P. Chaulagain, Kellie Sprague, Monika E. Pilichowska, Janet M. Cowan et autres

The risk of late complications including secondary malignancies is increased in long-term survivors of allogeneic hematopoietic stem cell transplants (HSCT). There is limited literature on the biological behavior and clinical features of squamous cell carcinoma (SCC) of head and neck post-HSCT. We …

us (code pays fourni par la source)

Comparative Analysis: Trend of Infectious Complications in Cord Blood (CB) Versus Peripheral Blood (PB) and Bone Marrow (BM) Stem Cell Transplant (SCT) Per Hcup-NIS Database, 2002-2014

Amandeep Godara, Nauman Saleem Siddiqui, Hilal Hachem, Kellie Sprague

Background: Cord blood transplants are considered a viable alternative for patients with no available sibling or HLA matched donors. CB transplants are overall associated with delayed engraftment. Infectious complications are considered more common in CB transplant recipients, contributing significantly to post-transplant morbidity …

us (code pays fourni par la source)

Risk Factors for Occurrence and Outcome of Acute Graft Versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant: Analysis of 7 Year Health Care Utilization Project Data

Nauman Saleem Siddiqui, Mohammad Saud Khan, Zubair Hanif Khan, Hermann Simo et autres

Introduction: Acute Graft versus Host Disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplant (allo-HSCT). Despite advances in prevention and treatment methods, it remains significant cause of morbidity and mortality in this group of patients. Most of the studies …

us (code pays fourni par la source)

Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy

Sandy Wai Kuan Wong, Denise Larivee, M Warner, Kellie Sprague et autres

us (code pays fourni par la source)

Toxicities, response and survival: Autologous stem cell transplantation for multiple myeloma over 25 years at a single center

Sandy Wai Kuan Wong, Melissa T. Warner, Alejandro Moreno‐Koehler, Athena Kritharis et autres

us (code pays fourni par la source)

Risk-Adapted Melphalan and Stem Cell Transplantation after Suboptimal Responses to Bortezomib-Based Initial Therapy in Patients with Systemic Light-Chain Amyloidosis (AL)

Sandy Wai Kuan Wong, Denise Larivee, Melissa T. Warner, Kellie Sprague et autres

Abstract The treatment of newly diagnosed patients with AL has dramatically improved with the use of the first-in-class proteasome inhibitor bortezomib in initial therapy (Kastritis et al., Haematologica, 2007). Overall hematologic response rates of 62% have been reported in a large series …

us (code pays fourni par la source)

Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare

Gunjan L. Shah, Aaron N. Winn, Pei‐Jung Lin, Andreas K. Klein et autres

Comorbidity is more common in older patients and can increase the cost of care by increasing toxicity. Using the SEER-Medicare database from 2000 to 2007, we examined the costs and life-year benefit of Auto-HSCT for MM patients over the age of 65 …

us (code pays fourni par la source)